TY - JOUR
KW - Neglected tropical diseases (NTDs)
KW - Public-private partnerships
KW - Leishmaniasis
KW - WHO special programme for research and Training in Tropical Diseases (TDR)
KW - Drugs for Neglected Diseases initiative (DNDi)
KW - priority review voucher
AU - Barbeitas MM
AB - <jats:p>This article examines the market devices designed to address the “market failure” surrounding neglected diseases, focusing on international drug-development activities for leishmaniasis. Using public-private partnerships and the US Food and Drug Administration's Priority Review Voucher as key examples, the article explores how these initiatives have transformed drug development for neglected diseases over time. By tracing the history of two drug candidates for leishmaniasis—miltefosine and Anfoleish—the analysis reveals how the market devices initially intended to de-risk drug development have been turned into financial assets, aligning with the profit-driven imperatives of large pharmaceutical companies. This process, known as assetization, is examined through a long-term perspective that highlights the interaction between global health actors, pharmaceutical firms, and regulatory frameworks. The case of leishmaniasis offers a nuanced understanding of how commercial interests have shaped the market for neglected diseases, despite efforts to make them less neglected.</jats:p>
BT - Science, Technology & Human Values
DO - 10.1177/01622439251333913
LA - eng
M3 - Research Article
N2 - <jats:p>This article examines the market devices designed to address the “market failure” surrounding neglected diseases, focusing on international drug-development activities for leishmaniasis. Using public-private partnerships and the US Food and Drug Administration's Priority Review Voucher as key examples, the article explores how these initiatives have transformed drug development for neglected diseases over time. By tracing the history of two drug candidates for leishmaniasis—miltefosine and Anfoleish—the analysis reveals how the market devices initially intended to de-risk drug development have been turned into financial assets, aligning with the profit-driven imperatives of large pharmaceutical companies. This process, known as assetization, is examined through a long-term perspective that highlights the interaction between global health actors, pharmaceutical firms, and regulatory frameworks. The case of leishmaniasis offers a nuanced understanding of how commercial interests have shaped the market for neglected diseases, despite efforts to make them less neglected.</jats:p>
PB - SAGE Publications
PY - 2025
EP - 25
T2 - Science, Technology & Human Values
TI - Market Devices and the Assetization of Neglected Diseases: A Case Study of Leishmaniasis Drug Development
UR - https://journals.sagepub.com/doi/pdf/10.1177/01622439251333913
SN - 0162-2439, 1552-8251
ER -